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Dear Sophie,
I heard that your company had been acquired by that pharmaceutical giant, Portentis, accompanied by much rejoicing by
your investors. I wondered if you might return to Academe, and was a little surprised when you told me that you had
decided to join Portentis. Although I have never worked in a pharmaceutical company, being mainly and now
increasingly at the other end of their pipelines, I have had a little experience of them. This has been largely as a
spectator, and the few times I got into the court it was to pick up balls rather than hit them.
You will find it important to understand the nature of these enterprises. Although they believe they are acting in the
higher interests of humanity, ensuring our health and welfare, they are not averse to the considerations of the financial
resources of those who can buy their products. After all, they are under severe pressures from their investors to provide
the best return on the large sums spent on drug discovery, research and clinical development. You do not make much
money from malaria, but give them something like male impotence and they will rise to the occasion.
Their drug pipeline is sacred and this they guard as savagely as any oil potentate, constantly filling it at one end and
hoping that enough will emerge from the other end to keep their stock price up. Any hiccup in the pipeline makes for a
very uncertain future and generally leads the company to find a partner; each partner has the intention of gobbling up
the good parts of the other, while shedding everything that is tasteless and inedible in the process. You have to realise
that when this results in the loss of 4,000 people that is equivalent to having an extra billion dollars a year. That is almost
as good as having a new drug — perhaps not a blockbuster but at least a chipbuster.
The second thing you will learn is that these giant organisations have deep management problems. Lyndon Johnson
once said that he would rather have somebody in the tent, pissing out, than somebody outside the tent, pissing in. The
trouble with the companies is that everybody is inside the tent, pissing in and doing a lot more besides. Not only is their
static structure complicated, but they are forever reorganising themselves, wondering whether they should be based on
disease areas, or technology or locality. They are intensely hierarchical, with a well-defined reporting structure going
upwards from the coalface through supervisors, managers, senior managers, directors, and vice-presidents to the CEO at
the very top. He also has a board to report to and the board has a Chairman.
I have observed that these channels act as modulators certainly of amplitude but of frequency as well. Thus a
problem at the lower level is not actually solved but is polished enough to soften the bad news, and exported to the level
above. When this process is repeated several times, it results in a bland product, unrelated to any reality. You will find
that all decisions made at the top on its basis are not very good ones, because those at the top are unaware that any
problems exist. The reverse process is similar. A clear enough command can be given at the top, but as it passes
downwards it undergoes fragmentation and bits fall off and are lost, so by the time it reaches the bottom, where people
have to do something about it, they do not understand it. In most organisations with a cumbersome bureaucracy,
entrepreneurs will find short-cuts, but this is not possible in the unstable environment of big pharma because nobody is
around for long enough at any job to find these noiseless channels.
This is apparent to any academic who collaborates with the industry. They begin with a few thousand enemies, the
research department of the company, who believe that it is their money that the company is proposing to give away. To
counter this, the academic needs somebody in the company to champion their cause. When, after lengthy negotiations
with everybody, including the lawyers, the contract is finally signed, they may think they have reached the end and can
begin research, but it is only the beginning, because the collaboration will need to be monitored and to an extent that is
proportional to the sum of money given.
If you become a champion you will find that as time goes on you will vanish, either because you are successful and
have moved up, or — most improbably in your case — because you have not been successful and have been moved
sideways into technology acquisition or report writing. With this loss, the level of ignorance of those monitoring the
collaboration rises abruptly and, of course, they too are soon on the move, so that in three years there is nobody that
understands the project or why it was ever supported.
I could of course give you a more detailed guide to the tricky paths in your new terrain, so please give me a call. If
I’m not in, the chances are that I’ve gone to the pharmacy for my prescriptions.
Your ever-loving Grandpa Syd
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